The first results are hopeful, but the number of the patients was small, so we are enlarging the enrollment in the expectation of corroborating our results soon.
Introduction: Abnormal blood levels of various trace elements have not been consistently studied in the end-stage renal disease. The uremic patients treated by chronic dialysis lose one important route of trace elements excretion and are exposed to an artificial environment of the dialysis fluid. The process may lead to depletion of biologically essential substances or its accumulation in the patient. Thus, dialysis patients are at risk for both deficiency and accumulation of trace elements, depending on dietary intake, residual kidney function and removal by dialysis. Aim of the study:The present study was pointed to investigate possible existence of trace elements disturbances in uremic patients undergoing regular hemodialysis (HD) treatment and its relationship to some inflammatory markers.Material and methods: Blood samples of 56 patients on hemodialysis and 30 healthy controls were analysed twice in 3 months follow up period for quantitation of serum zinc, selenium and copper, serum albumins -transporters of the TE in the human body, and C-reactive protein (CRP) and interleukine-6 (Il-6) -two important markers of inflammation. Results:The study revealed that serum zinc and selenium concentrations in HD patients are distinctly decreased compared to that of healthy controls, and serum copper was found slightly abnormally increased. Significant negative correlation was found between Zn/CRP and Zn/Il-6 and positive one -between Cu/CRP and Cu/Il-6. Conclusion:Disturbances of trace elements are primarily the result of renal failure, but they may be further exacerbated by the dialysis procedure. Negative correlations between Zn and some inflammatory markers and positive -between them and Cu, probably suggest some influence of these TE on the inflammatory process in dialysis patients.
Introduction:We present a case of a 40-year-old woman with IVF gemellar pregnancy in the 28th week of gestation, with primary hyperparathyroidism which complicated the course of pregnancy causing acute pancreatitis and AKI, who was treated with CRRT and succesfully overcame a hypercalcemic crisis. Methods:Case report: On admission to the Obstetrics and gynecology clinic patient was somnolent, hypertensive, tachicardic, oliguric, respiratory stable with pretibial oedema. Laboratory data showed raised inflammatory markers, anemia, elevated serum amylases, urea, creatinine and hypokalemia. Abdominal ultrasound revealed an enlarged, voluminous pancreas, whereas chest radiograph showed a large left sided pleural effusion. An inital diagnosis of severe preeclampsia was determined, with suspected acute pancreatitis. Emergent cesarean delivery was performed. In the post partum period she was treated with isotonic saline infusions, antibiotic therapy (cephalosporins, carbapenems), antihypertensive drugs, anticonvulsants, antiedematous therapy with preventive doses of heparin. After two days she was transfered to the Intensive Care Unit. She was dyspnoic with compensated respiratory acidosis. Additional laboratory findings indicated high levels of serum lipases and severe hypercalcemia (total calcium: 3,99mmol/l, ionized calcium 2,47mmol/l, hyperphosphatemia 0,45mmol/l, high levels of parathyroid hormone 834pg/ml) and hypokalemia. CT of the chest and abdomen, revealed acute pancreatitis, bilateral pleural effusions and signs of AKI. Endocranial MR showed signs of brain edema. US of the thyroid and parathyroid gland identified a cystic formation with clear borders and intranodular vascularisation in the parenchyma of the lower left lobe, size 9x13x26mm, resembling an enlarged parathyreoid gland. Other causes of hypercalcemia were excluded. Results: Previous therapy was continued with the addition of hydration (rate of 200ml/h), proton -pump inhibitors, corticosteroids, bolus doses of furosemide and byphosphonates (calcitonin was unavailable). Two combined pre-dilution procedures were performed using heparin anticoagulation and normal calcium levels of 1,5mmol/l in the dialysate. Initially CVVHDF was started (Multifiltrate Kit 8 CVVHF 1000, surface 1,8m 2 ; flow dialysate 200-300ml/h; blood flow 180-100ml/h; dialytic fluid/substitute ratio was 1:1) and further changed to CVVH with continuous potassium substitution. After the first CRRT procedure, a decrease in calcium levels was noted, with tendency for further reduction, resulting in desired (total calcium 2,23mmol/l, ionized calcium levels 1.26mmol/l) and gradual normalisation of other laboratory findings. The patients state of consciousness improved, diuresis was established and complete hemodynamic stability was reached, after which, on the 12th day of treatment, she was transfered to the Clinic of endocrionology for further treatment. Conclusions: Combining CRRT modality with heparin anticoagulation and careful monitoring of electrolyte levels can contribute to adequate...
cephalic in 75%of cases. A preventive antiplatelets therapy was noted in 76% of cases. The cause of the failure was thrombosis in 51% of cases, aneurysm rupture in 36.5% and infection in 12.5% of cases. Only 12% of patients with AVF stenosis were treated with percutaneous transluminal angioplasty. Statistical analysis revealed that diabetes, smoking and obesity were independent risk factors of the failure of the first AVF with respectively (p¼0.001, p¼0.03 and p¼0.04). Conclusions: Stenosis constitutes the first complication of AVF. Among reported risk factors related to failure of the first AVF, HTA seems to be the first risk factor, followed by obesity, smoking and dyslipidemia, then by hypoalbuminia and diabetes. Late referral of patients initiating dialysis therapy can also impair patency rate and fistula function. Risk factors identification and secondary prevention are needed in the management of HD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.